Summary
CSLLY Chart
Australia says CSL unit Seqirus to discontinue Benpen injections from November
Australia's drug regulator said on Wednesday it was notified by biopharmaceutical giant CSL's unit Seqirus that it will be discontinuing all strengths of their Benpen injection products progressively due to commercial reasons.
CSL Limited (CSLLY) Shareholder/Analyst Call Transcript
CSL Limited (CSLLY) Shareholder/Analyst Call Transcript
CSL: The Plasma Moat Is Being Rebuilt While The Market Prices The Noise
CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by FY28, with 60% of FY26 savings already implemented. Vifor segment delivers robust growth, offsetting iron franchise declines; new products like ANDEMBRY and HEMGENIX drive future momentum.
CSL Limited Sponsored ADR Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MD Michelle Dubey Yousif Capital Management LLC | 28,986 | $1.46M | $622,329.42 | -$838,578.38 | -57.4% |
CSL Limited Sponsored ADR (CSLLY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has CSL Limited Sponsored ADR ever had a stock split?
CSL Limited Sponsored ADR Profile
| Biotechnology Industry | Healthcare Sector | Gordon Naylor DipCompSc CEO | OTC PINK Exchange | 12637N204 CUSIP |
| AU Country | 32,698 Employees | 11 Mar 2026 Last Dividend | 2 Mar 2026 Last Split | - IPO Date |
Overview
CSL Limited is a globally prominent biopharmaceutical and vaccine company with its roots firmly planted in Melbourne, Australia since 1916. The company has carved out a significant presence not only in its home country but also across vital markets in the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and beyond. CSL Limited operates with a strategic focus on research, development, manufacturing, marketing, and distribution of innovative biopharmaceutical and vaccine solutions. It is organized into three main segments: CSL Behring, CSL Seqirus, and CSL Vifor, each targeting specific healthcare needs worldwide. Additionally, CSL Limited actively engages in licensing its intellectual property, underscoring its contributions to advancing global healthcare technologies and treatments.
Products and Services
- CSL Behring
This segment caters to a variety of healthcare needs through its diverse portfolio of products. CSL Behring is renowned for its plasma products, contributing to therapies for immunodeficiencies and rare diseases. It also pioneers in gene therapies, offering cutting-edge treatments for genetic disorders. Furthermore, CSL Behring provides recombinant products, marking significant advances in biotechnology for therapeutic uses.
- CSL Seqirus
Specializing in influenza-related products, CSL Seqirus stands out for its proactive approach towards flu prevention and pandemic preparedness. It offers a breadth of seasonal flu vaccines, ensuring public health safety across the globe. Additionally, CSL Seqirus collaborates with governments worldwide, offering pandemic services and solutions aimed at combating influenza outbreaks efficiently and effectively.
- CSL Vifor
With a keen focus on iron deficiency and nephrology, the CSL Vifor segment advances medical treatments in these crucial therapeutic areas. By developing and distributing specialized products, CSL Vifor addresses a range of conditions related to kidney health and iron metabolism, providing essential solutions for patients suffering from these ailments.
